This is a test post
This is a test article without using elementor Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Donec odio. Quisque volutpat mattis eros. Nullam malesuada erat ut turpis. Suspendisse urna nibh, viverra non, semper suscipit, posuere a, pede. Donec nec justo…
BRIM Biotechnology receives FDA Orphan Drug Designation for BRM424 to treat neurotrophic keratitis
Taipei, Taiwan, 8th December 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye…
BRIM Biotechnology, Inc. raises $20 million in Series E funding round
Taipei, Taiwan, 1st December 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that it has raised $20 million in its Series E funding…
BRIM Biotech submits US Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease to the FDA
Taipei, Taiwan, Nov 16th, 2022, BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) announced today that it has officially submitted the Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease (DED) to the U.S. Food and Drug Administration…
BRIM Biotechnology receives FDA agreement on Phase 3 clinical trial design for BRM421, BRIM’s lead candidate for Dry Eye Disease, at End of Phase 2 Meeting
Taipei, Taiwan, 1st November, 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate…
BRIM Biotechnology Board of Directors approves seasoned equity offering of USD 18 million to accelerate phase 3 development of lead asset BRM421 for dry eye syndrome
Taipei, Taiwan, August 12th, 2022/ BRIM Biotechnology, Inc. (BRIM, TPEx 6885) reports that the Company’s Board of Directors has approved a proposal for a seasoned equity offering, following its recent emerging stock market (ESM) listing, to increase capital and advance…
The road to regeneration: Could regenerative peptide therapy pave the way for new treatment methods for severe dry eye?
Severe dry eye disease (DED) affects the productivity and quality of life of millions of people. Prompted by the prevalence of this chronic condition, many pharmaceutical companies have set out in search of more robust treatments. Solutions have thus far…
BRIM Biotechnology enters Emerging Stock Market in Taiwan
Taipei, Taiwan, 23 rd June 2022 / BRIM Biotechnology, Inc. (BRIM, TPEx 6885) enters the Emerging Stock Market (ESM) in Taiwan on 23 rd June 2022, CST. The news was announced at the company’s first earnings call on 22 nd…
A Team Approach to Translational Science
Success doesn’t just come from a winning idea or an exciting new concept. Success comes from having a dedicated team behind that idea, with the enthusiasm and commitment to drive it from concept to clinic. The people behind the peptide…
BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Syndrome
Taipei, Taiwan, May 17th, 2022: BRIM Biotechnology, Inc. (“BRIM”) a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. (“ORA”) the world’s leading, ophthalmic research organization, for the late-stage…
